312 related articles for article (PubMed ID: 28219368)
1. Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study.
Komaki K; Kusaba T; Tanaka M; Kado H; Shiotsu Y; Matsui M; Shiozaki A; Nakano H; Ishikawa T; Fujiwara H; Konishi H; Itoh Y; Matoba S; Tamagaki K
BMC Cancer; 2017 Feb; 17(1):144. PubMed ID: 28219368
[TBL] [Abstract][Full Text] [Related]
2. Lower Blood Pressure-Induced Renal Hypoperfusion Promotes Cisplatin-Induced Nephrotoxicity.
Mizuno T; Hayashi T; Shimabukuro Y; Murase M; Hayashi H; Ishikawa K; Takahashi K; Yuzawa Y; Yamada S; Nagamatsu T
Oncology; 2016; 90(6):313-20. PubMed ID: 27225867
[TBL] [Abstract][Full Text] [Related]
3. Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.
Ikemura K; Oshima K; Enokiya T; Okamoto A; Oda H; Mizuno T; Ishinaga H; Muraki Y; Iwamoto T; Takeuchi K; Katayama N; Okuda M
Cancer Chemother Pharmacol; 2017 May; 79(5):943-949. PubMed ID: 28364288
[TBL] [Abstract][Full Text] [Related]
4. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
[TBL] [Abstract][Full Text] [Related]
5. Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia.
Prasaja Y; Sutandyo N; Andrajati R
Asian Pac J Cancer Prev; 2015; 16(3):1117-22. PubMed ID: 25735341
[TBL] [Abstract][Full Text] [Related]
6. Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer.
Shord SS; Thompson DM; Krempl GA; Hanigan MH
Anticancer Drugs; 2006 Feb; 17(2):207-15. PubMed ID: 16428940
[TBL] [Abstract][Full Text] [Related]
7. Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.
Hinai Y; Motoyama S; Niioka T; Miura M
J Clin Pharm Ther; 2013 Dec; 38(6):498-503. PubMed ID: 24102360
[TBL] [Abstract][Full Text] [Related]
8. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study.
Yoshida T; Niho S; Toda M; Goto K; Yoh K; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y
Jpn J Clin Oncol; 2014 Apr; 44(4):346-54. PubMed ID: 24503028
[TBL] [Abstract][Full Text] [Related]
9. Understanding the Risk Factors and Long-Term Consequences of Cisplatin-Associated Acute Kidney Injury: An Observational Cohort Study.
Bhat ZY; Cadnapaphornchai P; Ginsburg K; Sivagnanam M; Chopra S; Treadway CK; Lin HS; Yoo G; Sukari A; Doshi MD
PLoS One; 2015; 10(11):e0142225. PubMed ID: 26556481
[TBL] [Abstract][Full Text] [Related]
10. Electrolytes supplementation can decrease the risk of nephrotoxicity in patients with solid tumors undergoing chemotherapy with cisplatin.
Minzi OMS; Lyimo TE; Furia FF; Marealle AI; Kilonzi M; Bwire GM; Malichewe C
BMC Pharmacol Toxicol; 2020 Sep; 21(1):69. PubMed ID: 32967726
[TBL] [Abstract][Full Text] [Related]
11. Telmisartan Exacerbates Cisplatin-Induced Nephrotoxicity in a Mouse Model.
Hosoda A; Matsumoto Y; Toriyama Y; Tsuji T; Yoshida Y; Masamichi S; Kohno T
Biol Pharm Bull; 2020; 43(9):1331-1337. PubMed ID: 32879207
[TBL] [Abstract][Full Text] [Related]
12. Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.
Saito Y; Kobayashi M; Yamada T; Kasashi K; Honma R; Takeuchi S; Shimizu Y; Kinoshita I; Dosaka-Akita H; Iseki K
Support Care Cancer; 2017 Feb; 25(2):481-487. PubMed ID: 27699503
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-induced human peripheral blood mononuclear cells' oxidative stress and nephrotoxicity in head and neck cancer patients: the influence of hydrogen peroxide.
Quintanilha JCF; Visacri MB; Sousa VM; Bastos LB; Vaz CO; Guarnieri JPO; Amaral LS; Malaguti C; Lima CSP; Vercesi AE; Moriel P
Mol Cell Biochem; 2018 Mar; 440(1-2):139-145. PubMed ID: 28828710
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin Nephrotoxicity and Longitudinal Growth in Children With Solid Tumors: A Retrospective Cohort Study.
Jiménez-Triana CA; Castelán-Martínez OD; Rivas-Ruiz R; Jiménez-Méndez R; Medina A; Clark P; Rassekh R; Castañeda-Hernández G; Carleton B; Medeiros M;
Medicine (Baltimore); 2015 Aug; 94(34):e1413. PubMed ID: 26313789
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors Associated with Cisplatin-Induced Nephrotoxicity in Patients with Advanced Lung Cancer.
Miyoshi T; Misumi N; Hiraike M; Mihara Y; Nishino T; Tsuruta M; Kawamata Y; Hiraki Y; Kozono A; Ichiki M
Biol Pharm Bull; 2016; 39(12):2009-2014. PubMed ID: 27904042
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for cisplatin-induced long-term nephrotoxicity in pediatric cancer survivors.
Arga M; Oguz A; Pinarli FG; Karadeniz C; Citak EC; Emeksiz HC; Duran EA; Soylemezoglu O
Pediatr Int; 2015 Jun; 57(3):406-13. PubMed ID: 25441241
[TBL] [Abstract][Full Text] [Related]
17. Kidney-protective Effect of Magnesium Supplementation in Cisplatin-containing Chemotherapy for Pediatric Cancer: A Retrospective Study.
Matsui M; Saito Y; Yamaoka S; Yokokawa Y; Morikawa Y; Makimoto A; Yuza Y
J Pediatr Hematol Oncol; 2018 Jul; 40(5):379-381. PubMed ID: 29683958
[TBL] [Abstract][Full Text] [Related]
18. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A
Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173
[TBL] [Abstract][Full Text] [Related]
19. Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer.
Kimura T; Ozawa T; Hanai N; Hirakawa H; Suzuki H; Hosoi H; Hasegawa Y
J Otolaryngol Head Neck Surg; 2018 Feb; 47(1):10. PubMed ID: 29394952
[TBL] [Abstract][Full Text] [Related]
20. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone.
Merouani A; Davidson SA; Schrier RW
Am J Nephrol; 1997; 17(1):53-8. PubMed ID: 9057954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
